Literature DB >> 8497566

Where injecting drug users receive HIV counseling and testing.

R O Valdiserri1, T S Jones, G R West, C H Campbell, P I Thompson.   

Abstract

In 1990, nearly 1.5 million human immunodeficiency virus (HIV) antibody tests were performed at publicly funded sites. Eight percent of those tests were performed for self-identified illegal injecting drug users (IDU). The authors examined data from 28 project areas using a client record data base that permitted an analysis of self-reported risk behavior by type of service delivery site. Among self-identified IDUs, 68 percent of those tested and 82 percent of those found to be seropositive had obtained HIV counseling and testing services in settings other than drug treatment centers. The findings indicate that HIV-prevention programs for IDUs need to be available in various service delivery settings, not just in drug treatment programs. Strong links and cooperation between sites offering HIV counseling and testing and sites providing drug treatment programs are important to preventing HIV transmission to and from IDUs.

Entities:  

Mesh:

Year:  1993        PMID: 8497566      PMCID: PMC1403379     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  9 in total

1.  Structuring HIV prevention service delivery systems on the basis of social science theory.

Authors:  R O Valdiserri; G R West; M Moore; W W Darrow; A R Hinman
Journal:  J Community Health       Date:  1992-10

2.  HIV seropositivity in community-recruited and drug treatment samples of injecting drug users.

Authors:  T M Lampinen; E Joo; S Seweryn; R C Hershow; W Wiebel
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

3.  HIV infection and AIDS risk behaviors among intravenous drug users entering methadone treatment in selected U.S. cities.

Authors:  R J Battjes; R W Pickens; Z Amsel
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

4.  Drug treatment and HIV seropositivity.

Authors:  L S Brown; W Burkett; B J Primm
Journal:  N Y State J Med       Date:  1988-03

Review 5.  HIV infection among intravenous drug users: epidemiology and risk reduction.

Authors:  D C Des Jarlais; S R Friedman
Journal:  AIDS       Date:  1987-07       Impact factor: 4.177

6.  Demographic characteristics, risk behaviors, and HIV seroprevalence among intravenous drug users by site of contact: results from a community-wide HIV surveillance project.

Authors:  J McCusker; B Koblin; B F Lewis; J Sullivan
Journal:  Am J Public Health       Date:  1990-09       Impact factor: 9.308

7.  Ineffectiveness of AIDS education and HIV antibody testing in reducing high-risk behaviors among injection drug users.

Authors:  D A Calsyn; A J Saxon; G Freeman; S Whittaker
Journal:  Am J Public Health       Date:  1992-04       Impact factor: 9.308

8.  Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus.

Authors:  L Solomon; R Frank; D Vlahov; J Astemborski
Journal:  Am J Public Health       Date:  1991-10       Impact factor: 9.308

9.  Sexually transmitted diseases in a population of intravenous drug users: association with seropositivity to the human immunodeficiency virus (HIV).

Authors:  K E Nelson; D Vlahov; S Cohn; M Odunmbaku; A Lindsay; J C Antohony; E W Hook
Journal:  J Infect Dis       Date:  1991-09       Impact factor: 5.226

  9 in total
  3 in total

1.  Community-wide HIV counselling and testing in central Massachusetts: who is retested and does their behavior change?

Authors:  J McCusker; G Willis; M McDonald; S M Sereti; B F Lewis; J L Sullivan
Journal:  J Community Health       Date:  1996-02

2.  Incidence of HIV among injection drug users entering drug treatment programs in four US cities.

Authors:  C S Murrill; D R Prevots; M S Miller; L A Linley; J E Royalty; M Gwinn
Journal:  J Urban Health       Date:  2001-03       Impact factor: 3.671

3.  A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV.

Authors:  Michelle A Lally; Sydney A Montstream-Quas; Sara Tanaka; Sara K Tedeschi; Kathleen M Morrow
Journal:  AIDS Patient Care STDS       Date:  2008-01       Impact factor: 5.078

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.